Regeneron Pharmaceuticals, Inc. (4REGN)
Summary
4REGN Chart
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications
Regeneron Pharmaceuticals, Inc. Dividends
Regeneron Pharmaceuticals, Inc. Earnings
| 30 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
| 31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
| 1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
| 30 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 11.38 Cons. EPS | 12.07 EPS |
| 31 Oct 2024 Date | | 11.69 Cons. EPS | 12.46 EPS |
| 1 Aug 2024 Date | | 10.61 Cons. EPS | 11.56 EPS |
Regeneron Pharmaceuticals, Inc. (4REGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Regeneron Pharmaceuticals, Inc. ever had a stock split?
Regeneron Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Leonard S. Schleifer M.D., Ph.D. CEO | XMIL Exchange | US75886F1075 ISIN |
| US Country | 15,158 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Products and Services
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
- EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
- Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
- Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
- REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
- Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
- Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
- ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
- ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.
Contact Information
